24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceuticals
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:04
“I have no doubt that Donald Trump is anti-Semitic”
11:32
Intel's workforce questions its future amid layoffs and shrinking benefits
22:43
Intel’s struggles deepen with $16.6 billion loss but AI chip growth provides hope
19:12
Lemonade shares soar after promising Q3 results
More stories
Buzz
Most popular
Daily
Weekly
1
Intel issues ultimatum to employees to decide whether to take severance or fight layoffs
2
From Intel to Meta: How high-tech giants are rethinking employee perks
3
Intel's workforce questions its future amid layoffs and shrinking benefits
4
Sequoia-backed Decart raises $21M in Seed funding to pioneer scalable, cost-efficient GenAI
5
High-tech sector steps up with new Israel-US flights as government fails to act
More news
Pharmaceuticals
20 stories about Pharmaceuticals
Teva's vision 2025: Building on momentum for future market leadership
04.08.24
|
Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
Teva posts impressive Q2 results, ups 2024 revenue forecast
31.07.24
|
Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
Cyber attack shuts down Israeli pharma company's distribution
17.06.24
|
Omer Kabir
Rekah, a prominent local producer of medicines, cosmetics, vitamins, and nutritional supplements, said it is working "to contain the incident, locate and thwart it, and restore compromised systems to operation"
Teva shares continue to surge, climb to highest mark in more than five years on Q1 results
08.05.24
|
Sophie Shulman
AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales
Why are Teva shares surging and how does it plan to keep it up
04.04.24
|
Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
"Until there is unity and equality here, Israel has no chance"
22.02.24
|
Sophie Shulman
At night, serial entrepreneur Michal Tsur doesn’t sleep, worrying about her son fighting in the army. During the day, she is busy with her third startup, Remepy, and dreaming of a new country - the same country for which she took to the streets as one of the leaders of last year’s protest against the judicial reform
Teva CEO: "The company played not to lose, now we’ll play to win"
21.02.24
|
Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
Teva CEO: Israel’s production capacity has not been affected by the war
08.11.23
|
Sophie Shulman
The Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.
The Israeli startup using spatial biology to provide better cancer treatment
02.01.22
|
Yafit Ovadia
Nucleai is looking at the way cells interplay and are interspersed within human tissue to develop precision medicine solutions
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Israel’s RedHill Biopharma testing oral pill that cures Covid-19 symptoms
28.02.21
|
Yafit Ovadia
Israeli pharmaceutical company creates treatment to help severe and moderately-ill patients; company generates $90 million in sales annually
Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold
12.10.20
|
Tzally Greenberg
A series of successful exits and investments see the Israeli fund balloon by 22% to hit $404 million since the start of the Covid-19 crisis
What’s behind the timed resurgence of lawsuits against Teva?
28.08.20
|
Sophie Shulman
The Israeli pharmaceutical giant was hit with three legal blows over the course of a few days
Hitting the Reset Button on Antibiotics
17.04.20
|
Viki Auslender
As the world faces the global threat of Covid-19 and the post antibiotic era, MIT researcher Regina Barzilay and her team are using AI to discover new chemical compounds for medical treatment
Pharmaceutical Company AstraZeneca Launches Digital Health Program in Israel
27.11.19
|
Meir Orbach
Alongside funding, the program will provide Israeli startups with mentorship and training
Teva Quarterly Report Meets Analyst Expectations
07.11.19
|
Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
Teva Overcomes One Hurdle, Many Still Ahead
23.10.19
|
Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
Teva to Close Missouri Plant, Report Says
29.08.19
|
Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
Rivals' Earning Reports Should Have Teva's Shareholders Worried
05.08.19
|
Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
Teva to Pay California $69 Million in Narcolepsy Drug Settlement
30.07.19
|
Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
More Articles
Please ensure Javascript is enabled for purposes of
website accessibility